Deals channel feed

Pfiz­er ax­es sick­le cell, be­ta tha­lassemia deal with Sy­ros

Last year

In­fin­i­ty and MEI scrap merg­er af­ter un­so­licit­ed bid, lack of share­hold­er sup­port

Last year

Up­dat­ed: Roche pays Al­ny­lam $310M cash to part­ner on RNAi can­di­date for heart dis­ease

Last year

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

Last year
Financing
Startups

Fa­heem Has­nain gets a $212M stake to­geth­er for his big PhI­II gam­ble — here’s why in­vestors are let­ting it ride

Last year
Bioregnum

Idor­sia sells off Asian op­er­a­tions, top drug li­cens­es to So­sei Hep­tares in $465M deal

Last year

A small Swiss biotech tack­les a huge glob­al health is­sue with a hand­off from GSK. But can it make any mon­ey from it?

Last year
Bioregnum

An­titrust en­forcers roll out draft guide­lines amid crack­down on phar­ma­ceu­ti­cal merg­ers

Last year

Biotech’s op­ti­mism is re­turn­ing amid signs of a bet­ter sec­ond half and a brighter 2024

Last year
Financing
Startups

Doc­tors with­out Bor­ders asks J&J not to en­force sec­ondary patents for TB drug af­ter gener­ic deal with non­prof­it

Last year
Pharma

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Last year
Startups
Cell/Gene Tx

Pfiz­er, Flag­ship al­ly on a $100M cash launch of a drug dis­cov­ery ex­pe­di­tion

Last year
Bioregnum

No­vo Nordisk inks re­search deal with RNA start­up with new de­liv­ery ap­proach

Last year
R&D

No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

Last year
R&D

Sanofi, Doud­na-found­ed Scribe Ther­a­peu­tics to tar­get sick­le cell dis­ease in new pact

Last year
Pharma

Eli Lil­ly's Pre­vail strikes po­ten­tial bil­lion-dol­lar AAV cap­sids deal with Sang­amo for neu­ro­log­i­cal dis­eases

Last year
Cell/Gene Tx

Moon­Lake’s im­munol­o­gy drug gets help of in­vest­ment bankers for po­ten­tial sale — Reuters re­port

Last year
Pharma

FTC says it wants more in­for­ma­tion about $43B Pfiz­er-Seagen deal

Last year
Pharma

Aca­dia gets more rights for Day­bue, fork­ing over $100M up­front af­ter an ‘im­pres­sive’ US launch

Last year

Lil­ly bets up to $1.9B on Ver­sanis' PhI­Ib weight loss drug alone and in com­bo with No­vo Nordisk's We­govy

Last year
Pharma

Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Last year
R&D

Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Last year
Startups

Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

Last year
Startups

EU or­ders Il­lu­mi­na to pay $476M fine over un­ap­proved Grail deal

Last year
Law
First page Previous page 30313233343536 Next page Last page
A service from the Financial Times